糖尿病并发症中HO-1的有效保护机制:叙述性综述
Jing-Jing Zhang1,2, Ping Ni3, Yi Song2
1Medicine Research Institute & Hubei Key Laboratory of Diabetes and Angiopathy, Xianning, Hubei, China.
Cell death discovery
|October 10, 2024
概括
血红氧酶1 (HO-1) 通过减少炎症和氧化应激,可以保护糖尿病并发症. 这种酶显示为治疗糖尿病及其各种健康问题的治疗点.
科学领域:
- 生物化学 生物化学
- 免疫学 免疫学 免疫学
- 代谢障碍 代谢障碍 代谢障碍
背景情况:
- 糖尿病的特点是高血糖,导致严重的并发症,如心血管疾病和脏疾病.
- 血氧酶1 (HO-1) 是一种具有抗氧化,抗炎和抗丧性质的关键酶,对于减轻糖尿病损伤至关重要.
研究的目的:
- 审查血红素氧酶1 (HO-1) 与糖尿病及其相关并发症的发病过程之间的复杂关系.
- 探索HO-1在调节免疫反应和与糖尿病相关的编程细胞死亡途径中的作用.
主要方法:
- 文献综述侧重于研究糖尿病和其并发症中的血氧酶1 (HO-1) 的研究.
- 分析HO-1在巨分化,树突细胞成熟和编程细胞死亡 (pyroptosis,ferroptosis) 中的参与.
主要成果:
- 血液氧化酶1 (HO-1) 诱导将巨细胞从一种促炎 (M1) 状态转移到一种抗炎 (M2) 状态.
- HO-1抑制树突细胞成熟,促进调节性T细胞反应,减少促炎性细胞因子.
- HO-1通过减少活性氧物种的产生来减轻氧化应激和炎症,并影响热和铁.
结论:
- 血氧酶1 (HO-1) 显著影响糖尿病并发症的发展和进展.
- HO-1 是一种有前途的治疗标,用于用于管理糖尿病及其多方面的并发症的新型治疗方法.
相关概念视频
Oral Hypoglycemic Agents: Biguanides and Glitazones
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
Type I Diabetes II: Pathophysiology
Type 1 diabetes mellitus arises from an immune-mediated destruction of pancreatic β-cells, resulting in an absolute deficiency of insulin. This process develops in genetically susceptible individuals when autoimmunity, environmental exposures, and immunologic dysregulation converge to trigger a targeted attack on the insulin-producing cells of the pancreas. The β-cells are located within the islets of Langerhans and are essential for regulating blood glucose by facilitating cellular uptake of...
Type II Diabetes I: Introduction
Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder characterized by insulin resistance, in which target tissues such as the liver, muscle, and adipose tissue respond poorly to insulin. It is also associated with inadequate compensatory insulin secretion, where pancreatic β-cells fail to produce sufficient insulin. Together, these abnormalities lead to persistent hyperglycemia.EtiologyT2DM develops through a complex interaction of genetic predisposition and environmental or...
Type II Diabetes II: Pathophysiology
PathophysiologyType 2 diabetes mellitus (T2DM ) is a chronic metabolic disorder characterized by insulin resistance and progressive pancreatic β-cell dysfunction, leading to impaired glucose homeostasis. It results from interactions among genetic predisposition, environmental factors, and metabolic stressors, such as overnutrition and a sedentary lifestyle.Insulin Resistance and Glucose DysregulationEarly T2DM involves insulin resistance in skeletal muscle, adipose tissue, and the liver.
Hypoglycemia
Hypoglycemia is a blood glucose level below 70 mg/dL. It commonly occurs in individuals using insulin or insulin-secreting drugs, but may also arise in non-diabetic conditions. People with type 1 diabetes are at the highest risk because they depend on exogenous insulin. People with type 2 diabetes are also at risk, especially when treated with insulin or medications such as sulfonylureas, which increase insulin release regardless of blood glucose levels. It develops when insulin levels exceed...
Diabetic Retinopathy
DefinitionDiabetic retinopathy is a microvascular complication of diabetes affecting the retinal blood vessels.Risk FactorsDiabetic retinopathy is present in almost all individuals with type 1 diabetes and more than 60% of those with type 2 diabetes after two decades of disease.The risk increases with poor glycemic control, hypertension, dyslipidemia, smoking, pregnancy, and puberty.Although cataracts and glaucoma are also more frequent in people with diabetes, retinopathy remains the leading...


